Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten
- Written by PR Newswire
- Accretive Commercialization Services Agreement covering six mature assets across critical care, cardiovascular, and metabolic disease leveraging Everest's existing commercial organization- Exclusive Greater China license to develop and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor that adds to...














